2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  4. TLK
  5. TLK2 Isoform
  6. TLK2 Inhibitor

TLK2 Inhibitor

TLK2 Inhibitors (2):

Cat. No. Product Name Effect Purity
  • HY-162426
    UNC-CA2-103
    		Inhibitor 99.26%
    UNC-CA2-103 is a TLK2 inhibitor with a human IC50 of 18 nM, and it exhibits high selectivity over TLK1 and the vast majority of other kinases. UNC-CA2-103 can be used in research related to breast cancer, glioblastoma and gastric cancer.
  • HY-149213
    LSD1/TLK1-IN-1
    		Inhibitor 99.20%
    LSD1/TLK1-IN-1 is an orally active LSD1, TLK1, TLK2, TTK inhibitor with an LSD1 IC50 of 0.247 μM. LSD1/TLK1-IN-1 suppresses phosphorylation of Nek1 at T141 and Rad9 at S328, abrogates the TLK1>Nek1>ATR>Chk1 axis, protects H3K4me1/2 from demethylation, and does not affect LSD2, MAO-A, or MAO-B. LSD1/TLK1-IN-1 induces apoptosis, bypasses cell-cycle arrest, suppresses tumor growth, acts as a weak D4R antagonist, downregulates PD-L1 expression, enhances T-cell killing response, inhibits gastric cancer cell proliferation, shows minimal toxicity, and has no significant effect on normal prostate cells. LSD1/TLK1-IN-1 can be used for the research of prostate cancer and gastric cancer.